Pacific Biosciences Of California (PACB) Capital Expenditures Growth (1y) (2011 - 2026)
Pacific Biosciences Of California (PACB) Capital Expenditures Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 181.14 Bn | 173.84 Bn | 6.27 Bn | -17.56% |
| 2 | Stryker | 128.35 Bn | 125.47 Bn | 3.81 Bn | 34.96% |
| 3 | Medtronic | 107.95 Bn | 98.73 Bn | 6.41 Bn | 6.32% |
| 4 | Boston Scientific | 68.16 Bn | 66.71 Bn | 3.61 Bn | -5.35% |
| 5 | Edwards Lifesciences | 47.67 Bn | 44.00 Bn | 1.29 Bn | 15.89% |
| 6 | GE HealthCare Technologies | 28.45 Bn | 26.17 Bn | 1.98 Bn | 106.98% |
| 7 | Dexcom | 28.45 Bn | 27.33 Bn | 750.30 Mn | -11.95% |
| 8 | Smith & Nephew | 26.83 Bn | 26.25 Bn | - | - |
| 9 | Koninklijke Philips | 25.36 Bn | 22.23 Bn | 2.07 Bn | -47.73% |
| 10 | Pacific Biosciences Of California | 422.03 Mn | 146.07 Mn | 12.84 Mn | 119.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 119.08% |
| Dec 31, 2025 | -46.75% |
| Sep 30, 2025 | 89.07% |
| Jun 30, 2025 | -62.81% |
| Mar 31, 2025 | -64.19% |
| Dec 31, 2024 | -20.11% |
| Sep 30, 2024 | -194.82% |
| Jun 30, 2024 | -34.79% |
| Mar 31, 2024 | 4.25% |
| Dec 31, 2023 | -58.73% |
| Sep 30, 2023 | -80.19% |
| Jun 30, 2023 | -43.57% |
| Mar 31, 2023 | 2.28% |
| Dec 31, 2022 | 72.55% |
| Jun 30, 2022 | 156.15% |
| Mar 31, 2022 | 807.23% |
| Dec 31, 2021 | 4,141.79% |
| Jun 30, 2021 | 391.85% |
| Mar 31, 2021 | 242.74% |
| Dec 31, 2020 | -52.48% |